TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34028361
Drug: Guided internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided internet-based cognitive behavioral therapy for insomnia (iCBT-I)
Study: 34105207
Drug: Anlotinib (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib (12 mg/day; days 1–14; 21 days per cycle)
Study: 35570513
Drug: Tele-Mindfulness Based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tele-Mindfulness Based Cognitive Therapy (tele-MBCT), 8 weekly live online sessions, average daily practice of 23.58±45.71 minutes.
Study: 33599270
Drug: Continue on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue on first-line therapy (control)
Study: 32947459
Drug: Cetaphil Cream,
Normalized name: Cetaphil Cream, topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetaphil Cream, Aveeno Eczema Therapy Moisturizing Cream, CeraVe Moisturizing Cream, Vaseline (applied to nonlesional skin of one forearm)
Study: 36086755
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) and electronic moxibustion (EM) cotreatment, 3 times a week for 6 weeks, alongside previously prescribed alpha blocker.
Study: 36086755
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group continued to use the previously prescribed alpha blocker alone for 6 weeks.
Study: 33544052
Drug: Operationalization of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operationalization of risk perception (susceptibility only, severity only, or combination of the two)
Study: 35446230
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) for generalized anxiety disorder (GAD)
Study: 32998206
Drug: Magnesium creatine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium creatine chelate (MgCr‐C) supplementation, 5500 mg (0.07 g/kg/d) in 4 capsules per day
Study: 32998206
Drug: Placebo (corn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (corn starch in identical 4 capsules)
Study: 35747502
Drug: Epidermal growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidermal growth factor receptor-targeted therapy
Study: 32901962
Drug: Root canal
Normalized name: Canal + Gel 10% for Root Canal Preparation Dental Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Root canal treatment with tissue-level restoration (TL group)
Study: 32901962
Drug: Root canal
Normalized name: Canal + Gel 10% for Root Canal Preparation Dental Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Root canal treatment with normal occlusal contacts (OC group)
Study: 32901962
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (healthy patients with root canal treatments)
Study: 32588401
Drug: Solriamfetol 75
Normalized name: solriamfetol 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solriamfetol 75 mg
Study: 35421771
Drug: Constant low-temperature
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant low-temperature cold spray (programme A; n = 47)
Study: 35421771
Drug: Low-to-normal temperature
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-to-normal temperature spray (programme B; n = 49)
Study: 35463348
Drug: Reduced-dose chemoradiotherapy
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced-dose chemoradiotherapy (rdCRT) (56 Gy) with weekly carboplatin
Study: 35307727
Drug: Oral enteral
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral enteral nutrition combined with microbial preparations
Study: 35307727
Drug: Traditional intestinal
Normalized name: pork intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional intestinal preparation (control)
Study: 35535772
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy for Insomnia (ACT‐I)
Study: 33951124
Drug: oral sulfate
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral sulfate solution (OSS)
Study: 32306008
Drug: Enteral nutrition
Normalized name: ENTERAL NUTRITION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral nutrition support in addition to chemotherapy
Study: 35606883
Drug: Evolocumab (140mg)
Normalized name: evolocumab 140 MG/ML
DrugBank: Evolocumab (DB09303)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Evolocumab (140mg) administration once within 72 h before CABG
Study: 35606883
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no administration)
Study: 35606883
Drug: Evolocumab (140mg)
Normalized name: evolocumab 140 MG/ML
DrugBank: Evolocumab (DB09303)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Evolocumab (140mg) administration
Study: 33533487
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MRI and Ki-67
Study: 34479601
Drug: IFN‐?1a (11?g
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN‐?1a (11?g or 3MIU) injected subcutaneously at day 1, 3, 7, and 10 in addition to standard of care
Study: 32141389
Drug: Intermittent second-line
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent second-line chemotherapy (capecitabine or non-pegylated liposomal doxorubicin, given as two times four cycles)
Study: 32141389
Drug: Continuous second-line
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous second-line chemotherapy (capecitabine or non-pegylated liposomal doxorubicin, given as eight consecutive cycles)
Study: 32141389
Drug: Intermittent second-line
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent second-line chemotherapy
Study: 32141389
Drug: Continuous second-line
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous second-line chemotherapy
Study: 34563875
Drug: Initial hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial hydroxyurea treatment for children with SCA and abnormal transcranial Doppler (TCD) velocities
Study: 35887829
Drug: Optilyte® infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optilyte® infusion
Study: 35887829
Drug: Geloplasma® infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Geloplasma® infusion
Study: 33440972
Drug: Sevoflurane inhalation
Normalized name: Sevoflurane Inhalation Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevoflurane inhalation without propofol infusion (group Sev)
Study: 33440972
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion (group Pro)
Study: 32144059
Drug: Single-Injection Paravertebral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-Injection Paravertebral Block (PVB)
Study: 32710391
Drug: CT-P13 (biosimilar
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-P13 (biosimilar infliximab) given as a single infusion of 5 to 10 mg/kg
Study: 35907935
Drug: Virtual reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality therapy (VRT) - active content
Study: 35907935
Drug: Virtual reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality therapy (VRT) - passive content
Study: 32860031
Drug: Vupanorsen 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vupanorsen 40 mg Q4W
Study: 32860031
Drug: Vupanorsen 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vupanorsen 80 mg Q4W
Study: 32860031
Drug: Vupanorsen 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vupanorsen 20 mg QW
Study: 35076327
Drug: Local oestrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local oestrogen (oestriol) therapy
Study: 33099947
Drug: Preoperative neo‐adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative neo‐adjuvant chemotherapy+surgery+postoperative radiotherapy
Study: 35426318
Drug: Cognitive‐Behavioral Transdiagnostic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐Behavioral Transdiagnostic Therapy (TD‐CBT)
Study: 32807162
Drug: Cinnamaldehyde (27
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnamaldehyde (27 μg/mL)
Study: 35429285
Drug: 101BHG‐D01 nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 101BHG‐D01 nasal spray (40 µg to 960 µg)
Study: 33141110
Drug: Intravenous patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous patient-controlled analgesia (oxycodone)
Study: 33141110
Drug: Nurse-administered oral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-administered oral oxycodone
Study: 34848133
Drug: Riociguat 2.5
Normalized name: riociguat 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riociguat 2.5 mg three times daily
Study: 33180322
Drug: LEAP CML-CP
Normalized name: methylcellulose (1500 CPS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEAP CML-CP recommended therapy
Study: 32506943
Drug: Antiphospholipid antibody
Normalized name: Egg Phospholipids
DrugBank: Egg phospholipids (DB14233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiphospholipid antibody IgG positivity in patients with dysglycaemia
Study: 35595254
Drug: Twice weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly factor VIII prophylaxis (10 U/kg)
Study: 35595254
Drug: Thrice weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice weekly factor VIII prophylaxis (10 U/kg)
Study: 35595254
Drug: Twice weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly factor VIII prophylaxis
Study: 35595254
Drug: Thrice weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice weekly factor VIII prophylaxis
Study: 33079180
Drug: Leronlimab (700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leronlimab (700 mg subcutaneously, repeated after 7 days in 17 of 23 patients)
Study: 34902549
Drug: ADAPT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADAPT plus treatment as usual (TAU)
Study: 35862871
Drug: Encorafenib 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encorafenib 450 mg once daily plus binimetinib 45 mg twice daily
Study: 35862871
Drug: Encorafenib 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encorafenib 300 mg once daily
Study: 33522396
Drug: Low fat
Normalized name: Low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low fat (LF) meal, 15 g of fat
Study: 33522396
Drug: Moderate fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate fat (MF) meal, 30 g of fat
Study: 33522396
Drug: High fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fat (HF) meal, 60 g of fat
Study: 33522396
Drug: High fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fat (HF) meal administered twice for reproducibility
Study: 35135619
Drug: ACTION intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACTION intervention (Acceptance and Commitment Therapy) plus treatment as usual
Study: 36376738
Drug: Spesolimab 600
Normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spesolimab 600 mg every 4 weeks
Study: 36376738
Drug: Spesolimab 600
Normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spesolimab 600 mg every 4 weeks (sensitivity analysis)
Study: 34296639
Drug: Neural mobilization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neural mobilization (straight leg raising and dorsiflexion with two‐ended slider), administered three times/week for six weeks
Study: 34296639
Drug: Standard postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard postoperative physical therapy program only
Study: 36190150
Drug: Piezoelectric implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piezoelectric implant site preparation (PISP)
Study: 34185551
Drug: Donafenib (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donafenib (0.2 g orally twice daily)
Study: 34185551
Drug: Sorafenib (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib (0.4 g orally twice daily)
Study: 36347056
Drug: Single high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single high-dose liposomal amphotericin
Study: 32728299
Drug: RSV F‐protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSV F‐protein nanoparticle vaccine
Study: 35449064
Drug: COVID‐19 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID‐19 vaccine messaging platforms (4‐min video, one‐page informational flyer, brief scripted face‐to‐face message delivered by an ED physician or nurse) during intervention weeks
Study: 34389605
Drug: Treat-to-target therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treat-to-target therapy
Study: 34590561
Drug: Self-made Qingyuan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-made Qingyuan Shenghua decoction (100 mL in the morning and 100 mL in the evening for 7 days)
Study: 34982098
Drug: Drug-Eluting Stent
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-Eluting Stent (DES) - NOVA intracranial sirolimus-eluting stent system
Study: 35698100
Drug: Nutritional therapy
Normalized name: nutritional therapy for GSD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional therapy group (arm A)
Study: 32144133
Drug: gefitinib +
Approvals — FDA: no, EMA: no, PMDA: no
Description: gefitinib + fulvestrant (G+F)
Study: 34163193
Drug: Fufang Zhenzhu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fufang Zhenzhu Tiaozhi capsule (FTZ) with basic treatment
Study: 36053020
Drug: TRAUMACEM V+
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TRAUMACEM V+ Injectable Bone Cement augmentation
Study: 33223395
Drug: PRN medication
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRN medication prescribed
Study: 33223395
Drug: PRN medication
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRN medication administered
Study: 33223395
Drug: PRN medication
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRN medication administration
Study: 33223395
Drug: Overall PRN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall PRN prescribing and administration
Study: 34291992
Drug: Enhanced standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced standard treatment (EST)
Study: 39581631
Drug: Cenerimod 4
Normalized name: Cenerimod
DrugBank: Cenerimod (DB12705)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenerimod 4 mg
Study: 32483139
Drug: Fentanyl 2
Normalized name: fentanyl 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 2 mcg/kg given 2 minutes before intubation
Study: 32483139
Drug: Fentanyl 2
Normalized name: fentanyl 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 2 mcg/kg given 1 minute before intubation
Study: 32483139
Drug: Fentanyl 2
Normalized name: fentanyl 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 2 mcg/kg given 3 minutes before intubation
Study: 36396519
Drug: Enoxaparin 40
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg for 14 days once daily
Study: 35903009
Drug: Fluoxetine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (10 mg)
Study: 36568722
Drug: Boswellia and
Normalized name: Menthol, Unspecified Form 7 g in 100 g / Camphor (Synthetic) 6 g in 100 g TOPICAL GEL [Max-Relief with Boswellia and Aloe Vera]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boswellia and ginger mixture (Memoral: 360 mg Boswellia and 36 mg ginger)
Study: 32233251
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (0.5 g diluted in 20 ml normal saline)
Study: 32829540
Drug: Triple antibiotic
Normalized name: Triple Antibiotic
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triple antibiotic paste
Study: 35285940
Drug: Higher BMI
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher BMI in estrogen receptor-positive (ER+) African ancestry patients
Study: 34019711
Drug: KBP-042 (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: KBP-042 (5, 7.5, 10, 20, 20 (evening), 40 μg)
Study: 34019711
Drug: KBP-042 (5-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: KBP-042 (5-40 μg)
Study: 34293413
Drug: Multicomponent chair-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent chair-based exercise intervention (16 weeks, twice a week, 60 min)
Study: 32769595
Drug: Epidural Steroid
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural Steroid Injection (ESI)
Study: 35986353
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg Tribulus terrestris supplement twice daily for 2 weeks
Study: 35986353
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules twice daily for 2 weeks
Study: 32515119
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) 10 mg/kg
Study: 34864678
Drug: Olfactory Training
Normalized name: BOS TAURUS OLFACTORY BULB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olfactory Training (OT), performed twice a day for 4 months
Study: 34864678
Drug: Control training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control training condition, performed twice a day for 4 months
Study: 33387346
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (positive controls with no treatment)
Study: 36147397
Drug: Single visit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single visit root canal therapy
Study: 36147397
Drug: Multiple visit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple visit root canal therapy
Study: 35379296
Drug: Sequential multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential multiple ascending doses of solnatide
Study: 34155991
Drug: Modified combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified combined program of physical therapy and ergotherapy (including PNF, balance training, upright posture correction, constraint‐induced movement therapy, dual task activities, stimulation of the affected side in daily activities, targeted therapy) for 3 months
Study: 33845853
Drug: Wearable activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wearable activity tracker (Fitbit Flex) combined with digital behaviour change resources and weekly challenges delivered via Facebook
Study: 32381562
Drug: CZP 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: CZP 200 mg every 2 weeks (Q2W) full maintenance dose
Study: 32381562
Drug: CZP 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: CZP 200 mg every 4 weeks (Q4W) reduced maintenance dose
Study: 32052925
Drug: Test warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test warfarin sodium tablet
Study: 32052925
Drug: Reference product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference product Coumadin (2.5 mg)
Study: 33792551
Drug: Group-based cessation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based cessation counseling and nicotine patches
Study: 33730752
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 0.25 mg/kg
Study: 35380718
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron supplementation
Study: 34048554
Drug: Delays of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delays of ≥3 days to concordant antibiotic treatment
Study: 34048554
Drug: Delays of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delays of 1-2 days to concordant antibiotic treatment
Study: 34048554
Drug: Delays in
Normalized name: Delayed Release Oral Granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delays in appropriate antibiotic treatment
Study: 34775223
Drug: Immediate goal‐dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate goal‐dose enteral nutrition (IGEN)
Study: 34775223
Drug: Gradual goal‐dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gradual goal‐dose enteral nutrition (GGEN)
Study: 36817812
Drug: Dracocephalum extract
Normalized name: Laccocephalum mylittae whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dracocephalum extract (250 mg, twice daily for one month)
Study: 36817812
Drug: Placebo (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (250 mg starch, twice daily for one month)
Study: 34547006
Drug: Black rice
Normalized name: Avobenzone 30 mg in 1 mL / Ensulizole 20 mg in 1 mL / Octinoxate 20 mg in 1 mL / Octocrylene 50 mg in 1 mL TOPICAL CREAM [Black Rice Platinum Absolute Youth SPF 15]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black rice extract (1 g/d)
Study: 34547006
Drug: Placebo (maltodextrin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (maltodextrin, 1 g/d)
Study: 33723806
Drug: Lemborexant 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lemborexant 25 mg
Study: 32887793
Drug: Placebo (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (400 mg corn oil)
Study: 35753841
Drug: Moderna COVID-19
Normalized name: Moderna COVID-19 Vaccine
DrugBank: Moderna COVID-19 Vaccine (DB15654)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderna COVID-19 Vaccine (mRNA-1273)
Study: 33883880
Drug: Rapid intravenous
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid intravenous injection of omeprazole (group A)
Study: 33883880
Drug: Continuous micropump
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous micropump infusion of omeprazole (group B)
Study: 32623487
Drug: Zoledronate 5
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronate 5 mg IV
Study: 32623487
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further active treatment